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For Better or Worse? Minireview
Telomerase Inhibition and Cancer
subunit of telomerase (called mTR) by the laboratory of
Carol Greider in 1995 (Blasco et al., 1995), which fol-
lowed the cloning of the human gene by Villeponteau
Titia de Lange* and Tyler Jacks²
*The Rockefeller University
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and coworkers (Feng et al., 1995). With this key gene in²Howard Hughes Medical Institute
hand, Greider teamed up with Ron DePinho to determineDepartment of Biology
the age- and cancer-associated consequences of ren-Massachusetts Institute of Technology
dering mice deficient for telomerase. While mice areCambridge, Massachusetts 02139
the mammalian species of choice for this sort of work
because of the ability to do targeted gene ablation in
embryonic stem (ES) cells (as well as the numerous toolsOver the past several years, the scientific and popular
available for studying tumor development in the mouse),press has been bubbling over with experimental findings
there are two important differences between mice andthat would seem to be setting the stage for a magic
humans regarding telomeres and telomerase regulation.bullet against cancer. The focus of this fervor is the
First, telomerase activity is less stringently repressed inenzyme telomerase, the reverse transcriptase responsi-
the somatic tissues of mice compared to humans; sev-ble for maintaining the telomeric DNA at the ends of our
eral tissues in the adult mouse show measurable telo-chromosomes. Telomeres are essential elements that
merase activity (Prowse and Greider, 1995). Second, theprotect chromosome ends from degradation and liga-
telomeres of mice are about 20 kb longer than humantion. Without their telomeric caps human chromosomes
telomeres, which are only 5±15 kb. Since telomeres onlyundergo end-to-end fusions, forming dicentric and
shorten by about 100 bp per cell division, mouse cellsmulticentric chromosomes that break in mitosis, activat-
lacking telomerase would require many more doublingsing DNA damage checkpoints and otherwise wreaking
to exhaust telomeric sequences compared to humanhavoc on the genome (Harley et al., 1990; Counter et
cells. Given these crucial differences, it is unlikely thatal., 1992; Harley, 1995; van Steensel et al., 1998). Telo-
mice normally use telomere erosion as a tumor suppres-merase is not active in most somatic tissues but is widely
sor mechanism. To circumvent this problem, the telo-activated in cancer cells (Kim et al., 1994; Shay and
merase-negative mice had to be bred for six generationsBacchetti, 1997). Its activity in tumors has been ex-
until their telomeres had been brought down to humanplained by the need of continuously dividing cells to
size.overcome the progressive loss of telomeric sequences
In the first report on the mTR mutant mouse in 1997,that results from the fact that DNA synthesis leaves
Blasco et al. reported that mice could tolerate the ab-a terminal stretch of unreplicated DNA (Watson, 1972;
sence of telomerase activity, not just in the first genera-Olovnikov, 1973).
tion but through at least five successive generations ofThe prevailing model holds that if not for activation of
interbreeding telomerase-deficient animals. Using em-
telomerase, incipient tumor cells would either undergo
bryo-derived fibroblasts (MEFs) from mice at the differ-
terminal growth arrest (senescence), or die, when their
ent generations (G2, G3, G4, etc.), they could show that
telomeres were whittled away to an unacceptably short telomere length declined over successive generations,
length (Counter et al., 1992). Thus, telomere shortening ultimately giving rise to cells with reduced telomeric
has been viewed as a tumor suppressor mechanism, signal by in situ hybridization and some of the antici-
and the near-universal phenomenon of telomerase acti- pated chromosomal effects such as end-to-end fusions.
vation in cancer would seem to define an Achilles' heel Therefore, these experiments confirmed that telomerase
of the tumor cell. According to the many proponents of was necessary for maintenance of telomeric sequences
this scenario, inhibition of this inappropriately expressed in mice, but it was not required for the initial develop-
enzyme would render the cells unable to maintain their ment and health of the animals, at least out to generation
telomeric DNA, resulting in tumor stasis or regression six (G6).
due to the growth inhibitory effects of excessive telo- Furthermore, these investigators found that the mTR2/2
mere erosion. Enthusiasm for telomerase drugs is also cells, even those derived from the sixth generation,
fueled by the absence of the enzyme from most normal could be cultured in vitro and, when transformed with
cells, predicting relatively mild side effects. viral oncogenes, gave rise to tumors in nude mice. Thus,
Although the search for telomerase inhibitors is well despite considerable correlative data from human stud-
justified, recent experiments in telomerase-deficient ies linking telomerase activation with cellular immortal-
mice have muddied the waters somewhat. While some ization in culture and tumorigenesis in vivo (Counter et
studies in the mouse indicate that the absence of telo- al., 1992; reviewed in Shay and Bacchetti, 1997), mouse
merase can, indeed, inhibit tumor development, other cells can proliferate and be transformed in the absence
results in the same system seem to suggest that anti- of telomerase activity. Although on the surface, these
telomerase drugs could have the inverse effect and pro- initial findings would seem to weaken the argument that
mote oncogenic transformation under certain circum- telomerase inhibition would be an effective anti-tumor
stances. What are we to think? strategy, the mean telomere length in the mTR mutant
Creating a Mouse Model System cells from generation six might still have been consider-
The story of telomerase-deficient mice begins with able, perhaps leading to a long phenotypic lag. Indeed,
it takes 300 population doublings before mTR2/2 ESthe isolation of the mouse gene for the essential RNA
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cells show a growth defect and 450 doublings before genotype mTR2/2;Ink4A2/2 developed considerably fewer
tumors compared to mTR1/1;Ink4A2/2 mice (or earlythey arrest completely (Niida et al., 1998). It may also be
the case that mouse cells more readily induce alternative generation mTR2/2;Ink4A2/2 animals). Approximately
half as many of the mTR mutant mice in this backgroundmechanisms of telomere stabilization such as the ALT
pathway observed in some immortalized human cells developed tumors compared to the controls, although
those tumors that did develop resembled tumors in the(Bryan et al., 1997).
Tumor Predisposition in Late Generation controls in terms of tissue of origin, aggressiveness, and
histological appearance. Thus, in this model, absence ofmTR2/2 Mice
Further characterization of the mTR mutant mice fo- telomerase function was found to have a significant impact
on the rate of development of detectable tumors. Oncecused on the late generation (G6) animals as well as
earlier generation animals at advanced age, and here formed, however, the telomerase-deficient tumors seem
to have progressed normally.again the data ran counter to expectation. While one
might have expected that telomerase-deficient mice The early stages of tumor formation were also as-
sessed using isolated cells from the late generationwould have reduced tumor incidence (or perhaps to
never develop tumors at all), in fact these animals have a mTR2/2;Ink4A2/2 embryos. In a classical focus formation
assay using the potent oncogene combination of mycmoderately increased frequency of spontaneous tumor
development compared to wild-type controls (Rudolph plus ras (Land et al., 1983), these double mutant cells
were found to give rise to fewer numbers of transformedet al., 1999). This increased tumor predisposition might
be explained by the loss of telomeric sequences giving foci compared to mTR1/1;Ink4A2/2 MEFs. Importantly,
cotransfection of a functional mTR gene along with therise to various forms of chromosomal damage and over-
all genomic instability, a hallmark of the cancer cell. oncogenes was able to rescue the defect in the
mTR2/2;Ink4A2/2 cells somewhat. Thus, in this geneticIndeed, high rates of chromosomal damage were de-
tected in certain cell types in these G6 mTR2/2 mice context, short telomere length and absence of telo-
merase function appear to negatively affect the transfor-(Lee et al., 1998; Rudolph et al., 1999). In some organ
systems (e.g., hematopoietic cells and developing germ mation process, and restoration of telomerase function
could partially overcome this effect.cells), telomere erosion was associated with reduced
proliferative capacity or apoptotic cell death. In these Chromosome analysis of transformed cells demon-
strated a high rate of end-to-end fusions in transformedsettings, the absence of telomerase function would ap-
pear to be having the expected negative effect on cellu- cells without telomerase activity and a marked reduc-
tion in such defects in cells with restored telomeraselar life span and viability. In the developing cancer cells
of these mice, however, such checkpoint functions function. The authors propose that the efficiency of
transformation of cells carrying the Ink4A deletion wasmight have been mutationally eliminated early on, lead-
ing to a state in which chromosomal damage is tolerated negatively affected by the induction of checkpoint
mechanisms, including those controlled by the p53and actually drives the development of a tumor. If this
conclusion is extrapolated to humans, then one imag- gene, in response to the loss of telomeric sequences
and the ensuing genomic damage.ines that the effect of treatment of human tumors with
telomerase inhibitors might be highly context depen- p53 Makes a Difference
The accompanying paper by Chin et al. (1999) furtherdent. In tumors in which such checkpoints were intact,
senescence or apoptosis might ensue after telomerase explores how p53 status modulates the effects of telo-
merase deficiency. Since loss of telomere function in-inhibitor treatment (this would be good), whereas in tu-
mors in which these pathways were already abrogated, duces extensive secondary DNA damage, a role for p53
in the mTR2/2 phenotype is expected. Indeed, they findthe antitelomerase treatment might promote tumor pro-
gression (this would be bad). that absence of p53 function can rescue some of the
cellular and organismal defects in the late generationReduced Tumorigenesis in Ink4A/mTR
Double Mutant Mice mTR mice, including apoptosis in spermatocytes and
infertility in G6 males and females, allowing furtherIn the most recent papers on the mTR null mouse, the
effects of genetic context in the response to telomere breeding. Consistent with a role for p53 in the cellular
response to telomere loss in late generation mTR2/2loss and the consequences for tumor formation are ad-
dressed directly. As in most things, context matters. MEFs, the authors show, using a number of assays, that
the p53 pathway is activated in these cells. As in otherTwo reports assessed the effects of combining the mTR
mutation with each of two tumor-promoting mutations: cases of induction of the p53 checkpoint (e.g., following
gamma irradiation of cultured cells), the G6 mTR2/2;p531/1a deletion in the Ink4A locus (which encodes the tumor
suppressors p16INK4A and p19ARF) and mutation of p53 MEFs showed reduced S phase fractions and more cells
in the G1 and G2 phases of the cell cycle. Elimination(Chin et al., 1999; Greenberg et al., 1999). In both cases,
the tumor suppressor mutations were initially crossed of p53 function largely relieved these cell cycle blocks,
and G6 mTR2/2;p532/2 MEFs were shown to be capableonto the mTR mutant background and then carried
through successive generations in the absence of telo- of active cell cycling. Thus, in developing male germ
cells in vivo and in MEFs in culture, absence of p53merase activity in order to bring the telomeres down to
a reasonably short starting length. function changed the fate of telomere-deficient cells,
from death to viability and from cell cycle arrest to pro-For those looking to the mTR mutant mouse to rein-
force the telomerase±cancer connection, the cross to gression. Precisely what p53 is responding to in these
settings is not known, but the high frequency of chromo-the Ink4A brought good news. Greenberg et al. (1999)
reported that following a two-step, in vivo carcinogene- somal defects present in late generation telomerase-
deficient cells makes it likely that activation of DNAsis protocol, late generation (G3±G5) animals with the
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damage signals is part of the process. In addition, it is the rate of cellular transformation is presumed to be
possible that the very short telomeres lack sufficient high and probably not limiting, thus focusing attention
TRF2, the telomeric capping protein required to sup- on later stages of tumorigenesis. Arguably, this situation
press the activation of p53 by chromosome ends (Karl- more closely resembles events in the clinic, where treat-
seder et al., 1999). ment traditionally focuses on inhibiting the growth of
However, absence of p53 was not able to fully rescue established tumors rather than on tumor initiation. As
all effects of prolonged telomerase deficiency. In G8 such, these findings on the mTR knockout mouse bode
mTR2/2;p532/2 male mice, histological defects and ab- well for future telomerase therapy. Moreover, even if
sence of germ cells were noted in testes, causing steril- telomerase inhibitors turn out to increase the mutation
ity. Therefore, p53-independent mechanisms must exist rate in human cancers, they would have this feature in
that can induce arrest and/or death when the loss of common with the majority of the current cancer thera-
chromosomal sequences is even more extensive. Like- peutics, and the short-term advantages of the drugs
wise, in experiments with human cells in culture, may still outweigh the minor risk of creating a more
p53-independent cell death mechanisms have been aggressive tumor by inducing additional mutations. In
suggested to account for the ªcrisisº phase that pre- the end, we must await the development and testing of
cedes the outgrowth of telomerase-positive immortal- telomerase inhibitors for use in human tumor cells. Only
ized clones (Shay et al., 1993). then will we know whether the mTR mutant mouse is
Tumor development is facilitated by mutations that pointing with its paws up or its paws down.
affect overall genomic stability. Given the high degree
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